NEW YORK, Feb. 22 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) today announced that the Company will focus on its new drug discovery programs targeting Hepatitis C, and drug-resistant bacterial and fungal infections, and will discontinue all development programs for pafuramidine maleate ("pafuramidine"), an investigational therapy. The decision was made in response to recent reports related to additional events identified in a cohort of volunteers in a safety study involving the drug.
The cause of the liver and kidney abnormalities in the volunteers is still speculative and additional time and resources will be used to further examine these abnormalities. However, Immtech believes that the potential risk associated with further treatment of African sleeping sickness patients outweighs the benefits of further development because these patients are generally located in places where medical care may not be readily available. Additionally, the potential benefit and resources required relative to potential risk to pneumocystis pneumonia (PCP) patients does not support further development for this target market. Therefore, the Company will direct its resources to concentrate on other drug programs. Immtech's licensing partners, PAR Pharmaceutical Companies, Inc. and BioAlliance Pharma SA, remain in full support of the Company.
Immtech was informed in late December 2007 that a sub-group of
volunteers in the safety study who were treated with pafuramidine
experienced liver abnormalities. In response to that finding, Immtech
announced that all clinical trials involving pafuramidine would be placed
on clinical hold pending completion of a comprehensive analysis of these
abnormalities. All volunteers now have norm
|SOURCE Immtech Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved